Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Small Cell Lung Carcinoma 1Respiratory Syncytial Virus Infections 1Prostatic Neoplasms 1Lung Neoplasms 1Genital Neoplasms, Male 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 4Nivolumab 4fludarabine 3aldesleukin 3Paclitaxel 3Ipilimumab 3Cyclophosphamide 3Carboplatin 3padeliporfin 2atezolizumab 2anlotinib 2Riluzole 2Gemcitabine 2vinflunine 1sipuleucel-T 1relatlimab 1palbociclib 1olaparib 1niraparib 1motexafin gadolinium 1luprolide acetate gel depot 1lenvatinib 1ixabepilone 1cabozantinib 1Therapeutics 1Suspensions 1Surveys and Questionnaires 1Sunitinib 1Specimen Handling 1Powders 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urogenital Neoplasms × Suspensions × Clear all
NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

NanOlogy, LLC

Phase 2 Terminated
1 enrolled 5 charts
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡